VRDN
Viridian Therapeutics Inc

9,432
Mkt Cap
$2.66B
Volume
970,739.00
52W High
$34.29
52W Low
$9.90
PE Ratio
-7.90
VRDN Fundamentals
Price
$27.90
Prev Close
$28.75
Open
$28.77
50D MA
$31.74
Beta
1.07
Avg. Volume
1.54M
EPS (Annual)
-$3.07
P/B
7.30
Rev/Employee
$2,111.89
$795.77
Loading...
Loading...
News
all
press releases
Wells Fargo & Company Forecasts Strong Price Appreciation for Viridian Therapeutics (NASDAQ:VRDN) Stock
Wells Fargo & Company boosted their price objective on shares of Viridian Therapeutics from $26.00 to $29.00 and gave the company an "equal weight" rating in a research report on Tuesday...
MarketBeat·13d ago
News Placeholder
More News
News Placeholder
Y Intercept Hong Kong Ltd Buys 52,414 Shares of Viridian Therapeutics, Inc. $VRDN
Y Intercept Hong Kong Ltd increased its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 430.3% in the third quarter, according to the company in its most recent filing with the...
MarketBeat·16d ago
News Placeholder
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have earned an average rating of "Moderate Buy" from the fifteen analysts that are covering the stock, Marketbeat.com reports...
MarketBeat·24d ago
News Placeholder
SG Americas Securities LLC Acquires 49,981 Shares of Viridian Therapeutics, Inc. $VRDN
SG Americas Securities LLC grew its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 411.8% in the third quarter, according to the company in its most recent Form 13F filing...
MarketBeat·1mo ago
News Placeholder
Viridian Therapeutics (NASDAQ:VRDN) Reaches New 52-Week High - Still a Buy?
Viridian Therapeutics (NASDAQ:VRDN) Sets New 52-Week High - Still a Buy...
MarketBeat·1mo ago
News Placeholder
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today...
Business Wire·1mo ago
News Placeholder
Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $40.00 at Truist Financial
Truist Financial cut their price objective on shares of Viridian Therapeutics from $41.00 to $40.00 and set a "buy" rating on the stock in a research report on Thursday...
MarketBeat·1mo ago
News Placeholder
Viridian Therapeutics Prepares for Transformational 2026
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today...
Business Wire·1mo ago
News Placeholder
Jennifer Tousignant Sells 2,272 Shares of Viridian Therapeutics (NASDAQ:VRDN) Stock
Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) insider Jennifer Tousignant sold 2,272 shares of the business's stock in a transaction on Wednesday, December 31st. The stock was sold at...
MarketBeat·1mo ago
News Placeholder
Viridian Therapeutics (NASDAQ:VRDN) Insider Sells $70,795.52 in Stock
Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) insider Jennifer Tousignant sold 2,272 shares of Viridian Therapeutics stock in a transaction that occurred on Wednesday, December 31st...
MarketBeat·1mo ago
<
1
2
...
>

Latest VRDN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.